Literature DB >> 21365175

LEOPARD syndrome (PTPN11, T468M) in three boys fulfilling neurofibromatosis type 1 clinical criteria.

Atilano Carcavilla1, Isabel Pinto, Rafael Muñoz-Pacheco, Raquel Barrio, Maria Martin-Frías, Begoña Ezquieta.   

Abstract

Noonan syndrome (NS) and neurofibromatosis type 1 (NF1) are well-defined entities. The association of both disorders is called neurofibromatosis-Noonan syndrome (NFNS), a disorder that has been related to mutations in the NF1 gene. Both NS and NFNS display phenotypic overlapping with LEOPARD syndrome (LS), and differential diagnosis between these two entities often represents a challenge for clinicians. We report on three patients (two brothers and a not-related patient) diagnosed as having NFNS. They fulfilled NF1 diagnostic criteria and had some features of NS. The three of them had hypertophic cardiomyopathy while neurofibromas, Lisch nodules, and unidentified bright objects on MRI were absent. PTPN11 gene assays revealed a T468M mutation, typical of LS. Thorough clinical examinations of the patients revealed multiple lentigines, which were considered to be freckling in the initial evaluation. We conclude that NF1 clinical criteria should be used with caution in patients with features of NS. Patients with hyperpigmented cutaneous spots associated with cardiac anomalies, even if fulfilling the minimal NF1 criteria for diagnosis, should be strongly considered for LS diagnosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21365175     DOI: 10.1007/s00431-011-1418-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  31 in total

1.  PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome.

Authors:  Kenjiro Kosaki; Taichi Suzuki; Koji Muroya; Tomonobu Hasegawa; Seiji Sato; Nobutake Matsuo; Rika Kosaki; Toshiro Nagai; Yukihiro Hasegawa; Tsutomu Ogata
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

2.  Clinical and molecular studies in a large Dutch family with Noonan syndrome.

Authors:  I van der Burgt; E Berends; E Lommen; S van Beersum; B Hamel; E Mariman
Journal:  Am J Med Genet       Date:  1994-11-01

3.  Neurofibromatosis type I gene mutation in a patient with features of LEOPARD syndrome.

Authors:  R Wu; E Legius; W Robberecht; M Dumoulin; J J Cassiman; J P Fryns
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

4.  Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.

Authors:  Christian Thiel; Martin Wilken; Martin Zenker; Heinrich Sticht; Raimund Fahsold; Gabriele-Charlotte Gusek-Schneider; Anita Rauch
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

5.  Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.

Authors:  Hilde Brems; Magdalena Chmara; Mourad Sahbatou; Ellen Denayer; Koji Taniguchi; Reiko Kato; Riet Somers; Ludwine Messiaen; Sofie De Schepper; Jean-Pierre Fryns; Jan Cools; Peter Marynen; Gilles Thomas; Akihiko Yoshimura; Eric Legius
Journal:  Nat Genet       Date:  2007-08-19       Impact factor: 38.330

Review 6.  What's new in the neuro-cardio-facial-cutaneous syndromes?

Authors:  Ellen Denayer; Eric Legius
Journal:  Eur J Pediatr       Date:  2007-07-05       Impact factor: 3.183

7.  Germline KRAS mutations cause Noonan syndrome.

Authors:  Suzanne Schubbert; Martin Zenker; Sara L Rowe; Silke Böll; Cornelia Klein; Gideon Bollag; Ineke van der Burgt; Luciana Musante; Vera Kalscheuer; Lars-Erik Wehner; Hoa Nguyen; Brian West; Kam Y J Zhang; Erik Sistermans; Anita Rauch; Charlotte M Niemeyer; Kevin Shannon; Christian P Kratz
Journal:  Nat Genet       Date:  2006-02-12       Impact factor: 38.330

8.  LEOPARD syndrome: clinical diagnosis in the first year of life.

Authors:  M Cristina Digilio; Anna Sarkozy; Andrea de Zorzi; Giuseppe Pacileo; Giuseppe Limongelli; Rita Mingarelli; Raffaele Calabrò; Bruno Marino; Bruno Dallapiccola
Journal:  Am J Med Genet A       Date:  2006-04-01       Impact factor: 2.802

9.  Clinical lumping and molecular splitting of LEOPARD and NF1/NF1-Noonan syndromes.

Authors:  Anna Sarkozy; Annalisa Schirinzi; Francesca Lepri; Irene Bottillo; Alessandro De Luca; Antonio Pizzuti; Marco Tartaglia; Maria Cristina Digilio; Bruno Dallapiccola
Journal:  Am J Med Genet A       Date:  2007-05-01       Impact factor: 2.802

Review 10.  Noonan syndrome.

Authors:  Ineke van der Burgt
Journal:  Orphanet J Rare Dis       Date:  2007-01-14       Impact factor: 4.123

View more
  4 in total

1.  PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain.

Authors:  Marianna Spatola; Christian Wider; Thierry Kuntzer; Alexandre Croquelois
Journal:  BMC Neurol       Date:  2015-04-16       Impact factor: 2.474

2.  LEOPARD syndrome: clinical dilemmas in differential diagnosis of RASopathies.

Authors:  Claudia Santoro; Giuseppe Pacileo; Giuseppe Limongelli; Saverio Scianguetta; Teresa Giugliano; Giulio Piluso; Fulvio Della Ragione; Mario Cirillo; Giuseppe Mirone; Silverio Perrotta
Journal:  BMC Med Genet       Date:  2014-04-26       Impact factor: 2.103

3.  Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.

Authors:  Leora Witkowski; Mitchell W Dillon; Elissa Murphy; Matthew S Lebo; Heather Mason-Suares
Journal:  Mol Genet Genomic Med       Date:  2020-02-27       Impact factor: 2.183

Review 4.  Molecular screening strategies for NF1-like syndromes with café-au-lait macules (Review).

Authors:  Jia Zhang; Ming Li; Zhirong Yao
Journal:  Mol Med Rep       Date:  2016-09-22       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.